Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

Phase 3 Completed 205 enrolled M Abdur Rahim Medical College and Hospital Chattogram General Hospital · collab Cox's Bazar 250 Bed District Sadar Hospital · collab First Affiliated Hospital Xi'an Jiaotong University · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Timeline

Start: 2020-08-15
Primary completion: 2021-01-30
Completion: 2021-02-10

Publications

Mohiuddin Chowdhury ATM, Kamal A, Abbas KU, Talukder S, Karim MR, Ali MA, Nuruzzaman M, Li Y, He S. Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial. Front Pharmacol. 2022 Apr 5;13:690726. doi: 10.3389/fphar.2022.690726. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Actemra IV Infusion	Unknown	8 mg/kg	Intravenous
Subject	Remdesivir	Small molecule	2.5 mg/kg	Intravenous
Subject	Remdesivir	Small molecule	100 mg	Intravenous

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

Summary

Timeline

Publications

Drugs

Indications